This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F12%3A43897432%21RIV13-MZ0-00064173/
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F12%3A43897432%21RIV13-MZ0-00064173
rdf:type
skos:Concept n13:Vysledek
dcterms:description
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. They are believed to originate from the interstitial cells of Cajal (ICCs) or from the precursors of ICCs. Most GISTs show an activating mutation in either the c-kit or platelet-derived growth factor receptor alpha (PDGFRA) gene. Tumor size, mitotic rate, and anatomic location correlate with potential malignancy and recurrence rate. A total of 12 patients were diagnosed to have GIST based on histology or immunohistochemistry of a biopsy or resection specimen obtained from the GI tract in the 2004-2009 period. The material was obtained using retrospective data collection. Tumors classified as GISTs with low and very low risk of progression are associated with a very good prognosis, with virtually all patients surviving 5 years. In patients with high risk or progressive diseases, the prognosis of 5-year survival is much poorer. The main therapeutic option is surgical removal of the tumor (resection or broad excision). Agents showing promise for patients with malignant forms of GISTs are tyrosine kinase receptor inhibitors. Although imatinib is currently used as a first line treatment for all patients with metastatic or unresectable GISTs, it is likely that this treatment will change in the future based on the underlying mutational status. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. They are believed to originate from the interstitial cells of Cajal (ICCs) or from the precursors of ICCs. Most GISTs show an activating mutation in either the c-kit or platelet-derived growth factor receptor alpha (PDGFRA) gene. Tumor size, mitotic rate, and anatomic location correlate with potential malignancy and recurrence rate. A total of 12 patients were diagnosed to have GIST based on histology or immunohistochemistry of a biopsy or resection specimen obtained from the GI tract in the 2004-2009 period. The material was obtained using retrospective data collection. Tumors classified as GISTs with low and very low risk of progression are associated with a very good prognosis, with virtually all patients surviving 5 years. In patients with high risk or progressive diseases, the prognosis of 5-year survival is much poorer. The main therapeutic option is surgical removal of the tumor (resection or broad excision). Agents showing promise for patients with malignant forms of GISTs are tyrosine kinase receptor inhibitors. Although imatinib is currently used as a first line treatment for all patients with metastatic or unresectable GISTs, it is likely that this treatment will change in the future based on the underlying mutational status.
dcterms:title
Gastrointestinal Stromal Tumors (GIST): A Single Center Experience Gastrointestinal Stromal Tumors (GIST): A Single Center Experience
skos:prefLabel
Gastrointestinal Stromal Tumors (GIST): A Single Center Experience Gastrointestinal Stromal Tumors (GIST): A Single Center Experience
skos:notation
RIV/00064173:_____/12:43897432!RIV13-MZ0-00064173
n13:predkladatel
n15:ico%3A00064173
n3:aktivita
n10:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n7:2013
n3:domaciTvurceVysledku
n11:5279208 n11:4297547 n11:4416481
n3:druhVysledku
n9:J
n3:duvernostUdaju
n4:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
137731
n3:idVysledku
RIV/00064173:_____/12:43897432
n3:jazykVysledku
n16:eng
n3:klicovaSlova
features; efficacy; resection; diagnosis; documentation; leiomyosarcomas; kit; imatinib mesylate; term-follow-up; of-function mutations
n3:klicoveSlovo
n5:imatinib%20mesylate n5:of-function%20mutations n5:documentation n5:resection n5:term-follow-up n5:diagnosis n5:leiomyosarcomas n5:features n5:kit n5:efficacy
n3:kodStatuVydavatele
BE - Belgické království
n3:kontrolniKodProRIV
[73C9B46D0D37]
n3:nazevZdroje
Acta Chirurgica Belgica
n3:obor
n14:FJ
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
3
n3:rokUplatneniVysledku
n7:2012
n3:svazekPeriodika
112
n3:tvurceVysledku
Kostka, Rodomil Koldová, Lidmila Gürlich, Robert
n3:wos
000300603000007
s:issn
0001-5458
s:numberOfPages
7